Psoriasis Market to Grow Positively at a Paltry CAGR During the Study Period | AbbVie Inc., Amgen Inc., AstraZenca, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Dr. Reddy's Laboratories, Eli Lilly and Company, Forward Pharma, Johnson and Johnso

DelveInsight's "Psoriasis - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Psoriasis market share of the individual therapies, current and forecasted Psoriasis market size from 2020 to 2034 segmented by seven major markets. The report also offers current Psoriasis therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Psoriasis market.

Download sample report @ https://www.delveinsight.com/report-store/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent Advancements in the Psoriasis Market:
AnaptysBio intends to out-license imsidolimab in 2024 and the company plans to present the data in second half of 2024 medical meeting.
In February 2023, Nimbus Therapeutics announced the closing of Takeda's acquisition of Nimbus Lakshmi and its tyrosine kinase 2 (TYK2) inhibitor program, which includes the oral, selective allosteric TYK2 inhibitor NDI-034858, now known as TAK-279.
In July 2020, the US FDA granted ODD for imsidolimab for treating patients with generalized pustular psoriasis.

Key Highlights from the Psoriasis market report:
Topical treatments are typically the first line of defense when treating psoriasis. Topical slow down or normalize excessive cell reproduction and reduce inflammation caused by psoriasis.
In October 2023, the US FDA approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe psoriasis in adults who are candidates for systemic therapy or phototherapy. It is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis.
In October 2023, the US FDA approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe psoriasis in adults who are candidates for systemic therapy or phototherapy. It is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis.
The launch of potential therapies by key players AnaptysBio, MoonLake Immunotherapeutics, Takeda, Evelo Biosciences, UNION Therapeutics, and others are expected to boost the psoriasis market in the coming years.
Know more about how the psoriasis market is growing @ https://www.delveinsight.com/report-store/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Psoriasis Overview
Psoriasis is a chronic autoimmune skin condition characterized by the rapid growth of skin cells, leading to thick, scaly patches on the skin's surface. It often involves periods of flare-ups and remission. The severity of psoriasis can vary widely, and the condition frequently requires ongoing management.

- Classification: Psoriasis is generally categorized into mild and moderate-to-severe forms. This classification depends on the extent of skin involvement, the severity of symptoms, and the impact on the patient's quality of life.

- Treatment Options: Management of psoriasis is tailored to the severity of the disease, comorbid conditions, and individual patient needs. Treatments include:
- Topical Therapies: Such as corticosteroids and vitamin D analogs.
- Systemic Therapies: Including oral medications and biologics.
- Phototherapy: Using ultraviolet light to reduce inflammation and slow down the growth of skin cells.

- Biologic Treatments: These have become a major component of psoriasis management, targeting specific pathways in the immune system. Notable biologics include:
- TNF Inhibitors: Such as ENBREL (etanercept) and REMICADE (infliximab).
- Interleukin Inhibitors: Such as STELARA (ustekinumab) and COSENTYX (secukinumab).
- Dual-Targeted Therapies: Like BIMZELX (bimekizumab), which targets both IL-17A and IL-17F.

- Emerging Treatments: Recent advances have introduced new options such as oral TYK2 inhibitors and nonsteroidal topical agents, broadening the range of available treatments and increasing competition in the market.

- Impact on Life: Psoriasis can significantly affect a person's quality of life, causing discomfort, psychological stress, and social stigma. Effective management is crucial for improving overall well-being.

The treatment approach for psoriasis is individualized, taking into account the specific characteristics and needs of each patient.

Psoriasis Epidemiological Insights
Psoriasis is prevalent worldwide with a global prevalence of 1% to 8%. It begins in childhood in approximately one-third of cases.
In 2023, the total number of diagnosed prevalent cases of psoriasis in the US was estimated to be around 8,000,000.
Among type-specific cases, approximately 68% of the psoriatic patients suffer from plaque psoriasis followed by inverse psoriasis in the US.
In 2023, approximately 28% of psoriasis patients in the US were estimated to suffer from genital psoriasis, followed by those with scalp psoriasis.
The most common form of Psoriasis is Plaque Psoriasis, affecting about 90% of psoriasis patients, with about 20%-30% of them suffering from a moderate or severe condition.
The study by Armstrong et al. (2021) highlighted the prevalence of psoriasis in adults in the US and how prevalence has changed since 2003. As per the findings, the prevalence of psoriasis in adults in the US was 3.0%. The study also mentioned that in children younger than 18 years, showed a psoriasis prevalence of 0.128%.
To know more epidemiological insights, visit: https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Psoriasis Market Outlook
Psoriasis is a chronic, relapsing condition that often requires long-term treatment. The choice of therapy is influenced by factors such as the severity of the disease, associated comorbidities, and access to healthcare. Patients with psoriasis are typically classified into two groups: those with mild disease and those with moderate-to-severe disease. This classification is based on the clinical severity of the lesions, the percentage of body surface area affected, and the impact on the patient's quality of life. The treatment market is primarily driven by TNF inhibitors, interleukin inhibitors, and vitamin D analogs. Recent developments include the increased use of biologic therapies, a growing focus on precision medicine, and the expansion of topical treatment options. The introduction of oral TYK2 inhibitors and nonsteroidal topical agents has further diversified treatment options and intensified market competition.

BIMZELX (bimekizumab-bkzx): BIMZELX is a monoclonal antibody used to treat moderate to severe plaque psoriasis. It works by targeting and inhibiting both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), cytokines involved in inflammation. In October 2023, the US FDA approved BIMZELX for adults with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy.

ENBREL (etanercept): ENBREL is a TNF blocker that consists of a dimeric fusion protein. It includes the extracellular ligand-binding portion of the human 75 kDa TNF receptor (TNFR) linked to the Fc portion of human IgG1.

REMICADE (infliximab): REMICADE is a TNF blocker approved by the US FDA for severe adult plaque psoriasis. It is a chimeric IgG1κ monoclonal antibody, combining human constant regions with murine variable regions, and has a molecular weight of about 149.1 kDa. It is produced by a recombinant murine myeloma cell line, SP2/0.

HUMIRA (adalimumab): HUMIRA is a recombinant human IgG1 monoclonal antibody, created using phage display technology. It features human-derived heavy and light chain variable regions and human IgG1 constant regions.

STELARA (ustekinumab): STELARA is a human IgG1κ monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 cytokines. It is produced using recombinant DNA technology in a well-characterized cell line and purified through standard bioprocessing methods.

COSENTYX (secukinumab): COSENTYX is a human biologic that specifically inhibits interleukin-17A (IL-17A). This cytokine plays a key role in inflammation and is involved in conditions such as psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA).

Promising Therapies in the Psoriasis Pipeline
Deucravacitinib
ARQ-151
ABBV-157
And others
Discover more about Psoriasis therapies in the pipeline @ https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Psoriasis Market are AbbVie Inc., Amgen Inc., AstraZenca, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Dr. Reddy's Laboratories, Eli Lilly and Company, Forward Pharma, Johnson and Johnson (Janssen Biotech Inc.), Leo Pharma AS, Merck and Co. Inc., Novartis AG, Pfizer Inc., Stiefel Laboratories Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, UCB SA, Valeant Pharmaceuticals, and others.
To understand key companies related to the Psoriasis Market, get a snapshot of the Psoriasis Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Psoriasis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Psoriasis Companies: Bristol Myers Squibb, Arcutis Biotherapeutics, AbbVie, and others
Key Psoriasis Pipeline Therapies: Deucravacitinib, ARQ-151, ABBV-157, and others
Therapeutic Assessment: Psoriasis current marketed and emerging therapies
Psoriasis Market Dynamics: Psoriasis market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Psoriasis Market Access and Reimbursement
Table of Contents
1. Psoriasis Market Key Insights
2. Psoriasis Market Report Introduction
3. Psoriasis Market Overview at a Glance
4. Psoriasis Market Executive Summary
5. Disease Background and Overview
6. Psoriasis Treatment and Management
7. Psoriasis Epidemiology and Patient Population
8. Patient Journey
9. Psoriasis Emerging Drugs
10. 7MM Psoriasis Market Analysis
11. Psoriasis Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Psoriasis Market Drivers
15. Psoriasis Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Request for a sample report @ https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight:

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.